A randomized controlled clinical study of Yi Shen Gu Kang Fang Formula (Yi Shen Qu Tong Granules) in the treatment of small cell lung cancer
- Conditions
- extensive stage small cell lung cancer
- Registration Number
- ChiCTR2400088796
- Lead Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Meet the western medical diagnostic criteria for small cell lung cancer and Chinese medicine diagnostic criteria for renal deficiency and positive deficiency, stasis and toxicity stagnation syndrome; <br>(2) First-line patients with evaluable lesions who have not previously received chemotherapy-targeted and immunotherapy;<br> (3) Small cell lung cancer patients who are to receive =2 cycles of immunization + platinum + etoposide first-line treatment;<br> (4) Uncomplicated or no previous history of other primary malignancies;<br> (5) Age 18-80 years with expected survival >12 months;<br> (6) Kasper score (KPS) = 60;<br> (7) Normal cognitive ability, can cooperate in filling out the questionnaire; <br>(8) Voluntary acceptance of the study protocol and signing of the informed consent form.
(1) Those with severe cardiac or cerebrovascular disease, severe hepatic or renal impairment, or infection;<br> (2) Those who have participated or are participating in other clinical trials within 3 months <br>(3) Those with a history of previous psychiatric disorders such as depression, obsessive-compulsive disorder, or schizophrenia; <br>(4) Those who require simultaneous radiotherapy; <br>(5) Those who are pregnant or breastfeeding.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival;tumor marker;
- Secondary Outcome Measures
Name Time Method TCM syndrome score ;QLQ-C30;Piper Fatigue Score;